Soleus Capital Management, L.P. Nurix Therapeutics, Inc. Transaction History
Soleus Capital Management, L.P.
- $1.18 Billion
- Q3 2024
A detailed history of Soleus Capital Management, L.P. transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Soleus Capital Management, L.P. holds 1,065,834 shares of NRIX stock, worth $21.3 Million. This represents 2.03% of its overall portfolio holdings.
Number of Shares
1,065,834
Previous 2,055,916
48.16%
Holding current value
$21.3 Million
Previous $42.9 Million
44.23%
% of portfolio
2.03%
Previous 4.35%
Shares
10 transactions
Others Institutions Holding NRIX
# of Institutions
181Shares Held
68.1MCall Options Held
78KPut Options Held
53.8K-
Black Rock Inc. New York, NY6.82MShares$136 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.28MShares$85.5 Million6.28% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.01MShares$80.2 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY3.88MShares$77.6 Million0.93% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.87MShares$77.3 Million3.2% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $942M
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...